Compared with normal VCR molecules, this novel compound displays definite targeting of CD44 + MV4-11 model leukemia cells, which contributes to enhancing its anti-leukemia influence in vitro and obviously improving the therapeutic efficacy in vivo [89]. This evidence concerns the gene CD44 and leukemia.